Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance

Giorgio Stassi, Simone Di Franco, Lidia Villanova, Micol Eleonora Fiori, Ruggero De Maria

Risultato della ricerca: Review article

13 Citazioni (Scopus)

Abstract

In the last decades, the role of the microenvironment in tumor progression and therapeutic outcome has gained increasing attention. Cancer-associated fibroblasts (CAFs) have emerged as key players among stromal cells, owing to their abundance in most solid tumors and their diverse tumor-restraining/promoting roles. The interplay between tumor cells and neighboring CAFs takes place by both paracrine signals (cytokines, exosomes and metabolites) or by the multifaceted functions of the surrounding extracellular matrix. Here, we dissect the most recent identified mechanisms underlying CAF-mediated control of tumor progression and therapy resistance, which include induction of the epithelial-to-mesenchymal transition (EMT), activation of survival pathways or stemness-related programs and metabolic reprogramming in tumor cells. Importantly, the recently unveiled heterogeneity in CAFs claims tailored therapeutic efforts aimed at eradicating the specific subset facilitating tumor progression, therapy resistance and relapse. However, despite the large amount of pre-clinical data, much effort is still needed to translate CAF-directed anti-cancer strategies from the bench to the clinic.
Lingua originaleEnglish
pagine (da-a)70-
Numero di pagine16
RivistaMolecular Cancer
Volume18
Stato di pubblicazionePublished - 2019

Fingerprint

Epithelial-Mesenchymal Transition
Neoplasms
Therapeutics
Exosomes
Tumor Microenvironment
Stromal Cells
Cancer-Associated Fibroblasts
Extracellular Matrix
Cytokines
Recurrence

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Oncology
  • Cancer Research

Cita questo

Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. / Stassi, Giorgio; Di Franco, Simone; Villanova, Lidia; Fiori, Micol Eleonora; De Maria, Ruggero.

In: Molecular Cancer, Vol. 18, 2019, pag. 70-.

Risultato della ricerca: Review article

@article{94767347f1d541bb95bbe56b2860577b,
title = "Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance",
abstract = "In the last decades, the role of the microenvironment in tumor progression and therapeutic outcome has gained increasing attention. Cancer-associated fibroblasts (CAFs) have emerged as key players among stromal cells, owing to their abundance in most solid tumors and their diverse tumor-restraining/promoting roles. The interplay between tumor cells and neighboring CAFs takes place by both paracrine signals (cytokines, exosomes and metabolites) or by the multifaceted functions of the surrounding extracellular matrix. Here, we dissect the most recent identified mechanisms underlying CAF-mediated control of tumor progression and therapy resistance, which include induction of the epithelial-to-mesenchymal transition (EMT), activation of survival pathways or stemness-related programs and metabolic reprogramming in tumor cells. Importantly, the recently unveiled heterogeneity in CAFs claims tailored therapeutic efforts aimed at eradicating the specific subset facilitating tumor progression, therapy resistance and relapse. However, despite the large amount of pre-clinical data, much effort is still needed to translate CAF-directed anti-cancer strategies from the bench to the clinic.",
author = "Giorgio Stassi and {Di Franco}, Simone and Lidia Villanova and Fiori, {Micol Eleonora} and {De Maria}, Ruggero",
year = "2019",
language = "English",
volume = "18",
pages = "70--",
journal = "Molecular Cancer",
issn = "1476-4598",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance

AU - Stassi, Giorgio

AU - Di Franco, Simone

AU - Villanova, Lidia

AU - Fiori, Micol Eleonora

AU - De Maria, Ruggero

PY - 2019

Y1 - 2019

N2 - In the last decades, the role of the microenvironment in tumor progression and therapeutic outcome has gained increasing attention. Cancer-associated fibroblasts (CAFs) have emerged as key players among stromal cells, owing to their abundance in most solid tumors and their diverse tumor-restraining/promoting roles. The interplay between tumor cells and neighboring CAFs takes place by both paracrine signals (cytokines, exosomes and metabolites) or by the multifaceted functions of the surrounding extracellular matrix. Here, we dissect the most recent identified mechanisms underlying CAF-mediated control of tumor progression and therapy resistance, which include induction of the epithelial-to-mesenchymal transition (EMT), activation of survival pathways or stemness-related programs and metabolic reprogramming in tumor cells. Importantly, the recently unveiled heterogeneity in CAFs claims tailored therapeutic efforts aimed at eradicating the specific subset facilitating tumor progression, therapy resistance and relapse. However, despite the large amount of pre-clinical data, much effort is still needed to translate CAF-directed anti-cancer strategies from the bench to the clinic.

AB - In the last decades, the role of the microenvironment in tumor progression and therapeutic outcome has gained increasing attention. Cancer-associated fibroblasts (CAFs) have emerged as key players among stromal cells, owing to their abundance in most solid tumors and their diverse tumor-restraining/promoting roles. The interplay between tumor cells and neighboring CAFs takes place by both paracrine signals (cytokines, exosomes and metabolites) or by the multifaceted functions of the surrounding extracellular matrix. Here, we dissect the most recent identified mechanisms underlying CAF-mediated control of tumor progression and therapy resistance, which include induction of the epithelial-to-mesenchymal transition (EMT), activation of survival pathways or stemness-related programs and metabolic reprogramming in tumor cells. Importantly, the recently unveiled heterogeneity in CAFs claims tailored therapeutic efforts aimed at eradicating the specific subset facilitating tumor progression, therapy resistance and relapse. However, despite the large amount of pre-clinical data, much effort is still needed to translate CAF-directed anti-cancer strategies from the bench to the clinic.

UR - http://hdl.handle.net/10447/349425

UR - https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-019-0994-2

M3 - Review article

VL - 18

SP - 70-

JO - Molecular Cancer

JF - Molecular Cancer

SN - 1476-4598

ER -